{"nctId":"NCT01531959","briefTitle":"Midodrine for the Treatment of Refractory Hypotension","startDateStruct":{"date":"2012-04"},"conditions":["Hypotension","Critical Illness"],"count":139,"armGroups":[{"label":"Midodrine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Midodrine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Midodrine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* Admitted to the SICU\n* Requiring IV vasopressors at a rate of less than 100 mcg/min of phenylephrine, or 8 mcg/min of norepinephrine, or 60 mcg/min of metaraminol; and unable to wean for more than 24 hours while still maintaining desired blood pressure goal\n\nExclusion Criteria:\n\n* Inadequate tissue oxygenation\n* Liver failure\n* Renal failure\n* Hypovolemic shock or hypotension due to adrenal insufficiency\n* Pregnancy\n* Severe organic heart disease\n* Urinary retention\n* Pheochromocytoma\n* Thyrotoxicosis\n* Midodrine as pre-admission medication\n* Any known allergies to midodrine\n* Enrollment in another clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time Until Discontinuation of IV Vasopressors","description":"Measured hours from initiation of midodrine until discontinuation of IV vasopressors","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]}]},{"type":"SECONDARY","title":"ICU Length of Stay","description":"Measured number of days from initiation of midodrine until discharge ready from the ICU","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospital Length of Stay","description":"Measured number of days from initiation of midodrine until discharged from hospital","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"14.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rates of ICU Readmission","description":"Number of patients initiated on midodrine that are readmitted back to ICU after being discharged to floor","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias","description":"Measured rates of hypertension (increase in systolic blood pressure to values higher than those set by the primary team or greater than 160 mmg), bradycardia (decrease in heart rate to values lower than those set by the primary team or less than 40 BPM), hemodynamically significant tachyarrythmias (greater than 20 mmhg decrease in systolic blood pressure).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":66},"commonTop":["Hypertension","Bradycardia","Atrial fibrillation","Nausea","Lab parameter change"]}}}